1,4-Dithiothreitol

Names

[ Name ]:
1,4-Dithiothreitol

[Synonym ]:
Cleland reagent chiral
2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-rel-
(2R,3R)-1,4-Disulfanyl-2,3-butanediol
1,4-Dithiothreitol
L-(−)-Dithiothreitol
1,4-Bissulfanylbutane-2,3-diol
DL-1,4-Dimercapto-2,3-dihydroxybutane
(2R,3R)-(-)-2,3-Dihydroxy-1,4-butanedithiol
1,4-Disulfanyl-2,3-butanediol
(R*,R*)-1,4-DIMERCAPTO-2,3-BUTANEDIOL
(2R,3R)-1,4-Disulfanylbutane-2,3-diol
2,3-Butanediol, 1,4-dimercapto-, (2R,3R)-
L-Dithiothreitol
EINECS 240-263-0
(2R*,3S*)-1,4-dimercaptobutane-2,3-diol
dithiothreitol
threo-2,3-Dihydroxy-1,4-butanedithiol
(−)-Cleland's Reagent
(2R*,3S*)-1,4-dimercapto-2,3-butanediol
(2R,3R)-(-)-1,4-Dimercapto-2,3-butanediol
(2R,3R)-1,4-Dimercapto-2,3-butanediol
UNII:T8ID5YZU6Y
L-Cleland's
1,4-Disulfanylbutane-2,3-diol
2,3-Butanediol, 1,4-dimercapto-
(±)-1,4-Dimercapto-2,3-butanediol
(2R,3R)-1,4-dimercaptobutane-2,3-diol
MFCD00064305

Biological Activity

[Description]:

L-Dithiothreitol is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

[Related Catalog]:

Research Areas >> Others

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Boiling Point ]:
364.5±42.0 °C at 760 mmHg

[ Melting Point ]:
42-44ºC

[ Molecular Formula ]:
C₄H₁₀O₂S₂

[ Molecular Weight ]:
154.251

[ Flash Point ]:
174.2±27.9 °C

[ Exact Mass ]:
154.012222

[ PSA ]:
118.06000

[ LogP ]:
0.07

[ Vapour Pressure ]:
0.0±1.8 mmHg at 25°C

[ Index of Refraction ]:
1.579

[ Storage condition ]:
−20°C

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: EK1612000

CHEMICAL NAME :: 2,3-Butanediol, 1,4-dimercapto-, L-threo-

CAS REGISTRY NUMBER :: 16096-97-2

LAST UPDATED :: 199612

DATA ITEMS CITED :: 1

MOLECULAR FORMULA :: C4-H10-O2-S2

MOLECULAR WEIGHT :: 154.26

WISWESSER LINE NOTATION :: SH1YQYQ1SH -L,THREO

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 179 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963- Volume(issue)/page/year: 15,600,1972

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H302-H312-H315-H319-H335

[ Precautionary Statements ]:
P261-P280-P305 + P351 + P338

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xn: Harmful;

[ Risk Phrases ]:
R21/22

[ Safety Phrases ]:
26-36/37

[ RIDADR ]:
UN 3335

[ WGK Germany ]:
3

[ RTECS ]:
EK1612000

[ Hazard Class ]:
9.0

[ HS Code ]:
2930909090

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2930909090

[ Summary ]:
2930909090. other organo-sulphur compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

Articles

Involvement of epigenetics and EMT-related miRNA in arsenic-induced neoplastic transformation and their potential clinical use.

Cancer Prev. Res. (Phila.) 8(3) , 208-21, (2015)

Exposure to toxicants leads to cumulative molecular changes that overtime increase a subject's risk of developing urothelial carcinoma. To assess the impact of arsenic exposure at a time progressive m...

The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells.

PLoS ONE 9(5) , e97697, (2014)

Patients with ER/HER2-positive breast cancer have a poor prognosis and are less responsive to selective estrogen receptor modulators; this is presumably due to the crosstalk between ER and HER2. Fatty...

Matrix stiffening and β1 integrin drive subtype-specific fibroblast accumulation in lung cancer.

Mol. Cancer Res. 13(1) , 161-73, (2015)

The crucial role of tumor-associated fibroblasts (TAF) in cancer progression is now clear in non-small cell lung cancer (NSCLC). However, therapies against TAFs are limited due to a lack of understand...